MEDP Medpace Holdings, Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1668397 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.4%
TTM net income YoY19.6%
TTM EPS YoY25.9%
Revenue 3-yr CAGR16.8%
Net income 3-yr CAGR23.8%
Margins
Gross margin—
Operating margin21.4%
Net margin18.2%
FCF margin23.5%
EBITDA margin22.3%
Returns
ROE117.9%
ROA25.5%
ROIC (approx.)—
Asset turnover1.40x
Leverage & solvency
Liabilities / assets74.6%
Debt / equity0.00x
Current ratio0.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $716.00M | $707.33M | $706.60M | $708.45M | $659.90M | $603.31M | $558.57M | $536.59M |
| SG&A expense | $51.77M | $48.10M | $47.92M | $44.92M | $48.08M | $46.66M | $57.90M | $45.43M |
| Operating income | $165.54M | $146.82M | $141.50M | $153.27M | $141.81M | $126.33M | $113.52M | $125.38M |
| Pretax income | $170.91M | $151.66M | $147.59M | $156.83M | $142.84M | $124.54M | $118.17M | $133.88M |
| Income tax | $33.45M | $30.30M | $23.72M | $21.70M | $31.70M | $34.28M | $3.58M | $16.86M |
| Net income | $137.46M | $121.36M | $123.87M | $135.13M | $111.14M | $90.26M | $114.59M | $117.02M |
| EBITDA | $171.97M | $153.38M | $148.25M | $160.16M | $148.62M | $133.11M | $120.22M | $132.52M |
| EPS (basic) | 4.92 | 4.31 | 4.35 | — | 3.95 | 3.16 | 3.77 | — |
| EPS (diluted) | 4.84 | 4.25 | 4.28 | — | 3.86 | 3.10 | 3.67 | — |
| Weighted avg. shares (diluted) | 28.37M | 28.55M | 28.96M | — | 28.82M | 29.14M | 31.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $705.32M | $502.69M | $652.68M | $497.05M | $285.35M | $46.33M | $441.44M | $669.44M |
| Receivables | $447.64M | $441.80M | $394.58M | $402.08M | $373.03M | $377.92M | $298.22M | $296.44M |
| Current assets | $1.25B | $1.05B | $1.14B | $989.62M | $737.28M | $520.80M | $821.44M | $1.03B |
| PP&E, net | $175.00M | $157.11M | $136.55M | $131.06M | $133.18M | $135.48M | $128.33M | $123.61M |
| Goodwill | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M |
| Intangibles | $32.95M | $33.11M | $33.27M | $33.42M | $33.66M | $33.89M | $34.13M | $34.37M |
| Total assets | $2.30B | $2.06B | $2.13B | $1.98B | $1.75B | $1.57B | $1.90B | $2.10B |
| Current liabilities | $1.50B | $1.44B | $1.35B | $1.34B | $1.28B | $1.22B | $1.12B | $1.10B |
| Total liabilities | $1.72B | $1.62B | $1.53B | $1.52B | $1.46B | $1.40B | $1.30B | $1.28B |
| Shareholders' equity | $584.94M | $433.86M | $598.31M | $459.07M | $293.64M | $172.35M | $593.61M | $825.54M |
| Shares outstanding | 27.97M | 27.91M | 28.56M | 28.37M | 28.17M | 28.09M | 29.84M | 30.63M |
| Cash flow statement | ||||||||
| Operating cash flow | $216.60M | $162.01M | $151.79M | $192.65M | $246.21M | $148.53M | $125.84M | $190.67M |
| Capital expenditure | $20.16M | $23.91M | $6.81M | $4.54M | $10.71M | $6.11M | $9.99M | $7.64M |
| Free cash flow | $196.44M | $138.10M | $144.97M | $188.12M | $235.50M | $142.41M | $115.84M | $183.02M |
| Investing cash flow | -$20.14M | -$23.89M | -$6.75M | -$4.47M | -$10.66M | -$6.02M | -$9.99M | -$7.56M |
| Financing cash flow | $6.50M | -$288.34M | $12.67M | $22.73M | $3.41M | -$540.56M | -$345.97M | -$168.61M |
| Depreciation & amortization | $6.42M | $6.55M | $6.75M | $6.89M | $6.81M | $6.78M | $6.69M | $7.14M |
| Stock-based compensation | $7.60M | $4.35M | $4.92M | $5.62M | $6.32M | $5.95M | $16.89M | $5.89M |
| Share buybacks | $0 | $294.76M | $0 | $0 | $4.57M | $540.91M | $371.90M | $169.87M |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.